…
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies to modulate gene expression in genetically defined diseases, with a lead program targeting facioscapulohumeral muscular dystrophy (FSHD) and additional pipeline candidates. Long-term growth may be driven by positive clinical and regulatory milestones, pipeline expansion or partnerships, and the commercial potential of disease-modifying treatments in rare neuromuscular disorders.
Principal risks include binary clinical trial and regulatory outcomes, dependence on a small number of programs with ongoing financing needs, and limited commercial track record.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M |
| Net income | -74.88M | -9.72M | -97.33M | -105.62M | -78.33M |
| Selling general administrative | 28.67M | 34.97M | 39.15M | 41.69M | 30.52M |
| Selling and marketing expenses | - | 1.48M | 2.52M | - | - |
| Gross profit | -1.39M | 16.61M | -69.00M | 6.34M | 19.16M |
| Reconciled depreciation | 1.39M | 1.59M | 2.25M | 2.41M | 2.52M |
| Ebit | -74.88M | -19.83M | -97.33M | -112.56M | -83.57M |
| Ebitda | -73.49M | -18.24M | -95.16M | -111.71M | -81.05M |
| Depreciation and amortization | 1.39M | 1.59M | 2.17M | 0.85M | 2.52M |
| Operating income | -84.77M | -21.90M | -110.66M | -112.56M | -81.05M |
| Other operating expenses | 84.77M | 101.90M | 113.47M | 118.48M | 100.22M |
| Interest expense | - | - | - | 2.69M | 2.72M |
| Non recurring | - | - | - | 0.43M | - |
| Income tax expense | - | - | 2.00M | -4.25M | -2.52M |
| Total revenue | 0.00M | 80.00M | 2.81M | 6.34M | 19.16M |
| Total operating expenses | 83.38M | 38.51M | 41.67M | 118.48M | 100.22M |
| Cost of revenue | 1.39M | 63.39M | 71.80M | - | - |
| Total other income expense net | 9.89M | 12.17M | 13.33M | 2.69M | 0.21M |
| Net income from continuing ops | -74.88M | -9.72M | -98.71M | -109.87M | -80.85M |
| Net income applicable to common shares | - | - | - | -109.87M | -80.85M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 366.28M | 260.72M | 257.69M | 226.69M | 235.00M |
| Other current assets | 5.17M | 5.56M | 3.73M | 4.37M | 4.20M |
| Total liab | 17.28M | 17.68M | 22.50M | 27.74M | 23.46M |
| Total stockholder equity | 349.00M | 243.03M | 235.19M | 198.94M | 211.54M |
| Deferred long term liab | - | - | - | 4.62M | - |
| Other current liab | 9.05M | 7.69M | 8.73M | 9.55M | 0.07M |
| Common stock | 0.07M | 0.05M | 0.06M | 0.05M | 0.04M |
| Capital stock | 0.07M | 0.05M | 0.06M | 0.05M | 0.04M |
| Retained earnings | -594.28M | -519.40M | -509.67M | -412.34M | -302.47M |
| Other liab | - | - | - | 0.20M | 4.26M |
| Other assets | - | - | - | 3.20M | 1.63M |
| Cash | 197.53M | 58.21M | 25.56M | 35.10M | 35.41M |
| Total current liabilities | 13.05M | 11.04M | 13.68M | 16.73M | 19.20M |
| Current deferred revenue | - | - | - | 0.93M | 4.71M |
| Net debt | -191.09M | -49.58M | -14.74M | -21.68M | -35.41M |
| Short term debt | 2.40M | 2.19M | 2.19M | 2.60M | 9.63M |
| Short long term debt total | 6.44M | 8.63M | 10.82M | 13.42M | 0.47M |
| Other stockholder equity | 943.04M | 762.25M | 744.94M | 612.02M | 514.36M |
| Property plant equipment | - | - | - | 6.91M | 7.37M |
| Total current assets | 357.48M | 249.92M | 242.20M | 207.52M | 226.00M |
| Net tangible assets | - | - | - | 198.94M | 211.54M |
| Short term investments | 154.77M | 182.81M | 210.66M | 167.82M | 182.75M |
| Net receivables | 1.07M | 3.34M | 2.25M | 1.08M | 4.11M |
| Inventory | - | - | - | -0.85M | -0.47M |
| Accounts payable | 1.59M | 1.16M | 2.76M | 3.64M | 4.79M |
| Accumulated other comprehensive income | 0.17M | 0.13M | -0.14M | -0.80M | -0.40M |
| Common stock total equity | - | - | - | 0.05M | 0.04M |
| Retained earnings total equity | - | - | - | -412.34M | -302.47M |
| Non currrent assets other | 1.74M | 1.21M | 2.01M | 3.20M | 1.63M |
| Non current assets total | 8.80M | 10.79M | 15.49M | 19.17M | 9.00M |
| Capital lease obligations | 6.44M | 8.63M | 10.82M | 13.42M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 31.03M | 32.23M | -91.41M | 14.38M | -127.96M |
| Change to liabilities | - | - | - | -4.40M | -10.25M |
| Total cashflows from investing activities | 30.72M | 32.23M | -36.69M | 12.41M | -129.67M |
| Net borrowings | - | - | - | -0.05M | -0.02M |
| Total cash from financing activities | 168.67M | 2.75M | 118.12M | 84.32M | 186.51M |
| Change to operating activities | - | - | - | -1.55M | 1.41M |
| Net income | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M |
| Change in cash | 139.32M | 32.76M | -9.54M | -0.31M | -21.64M |
| Begin period cash flow | 59.41M | 26.66M | 36.19M | 36.50M | 58.14M |
| End period cash flow | 198.73M | 59.41M | 26.66M | 36.19M | 36.50M |
| Total cash from operating activities | -60.06M | -2.22M | -90.97M | -97.05M | -78.48M |
| Issuance of capital stock | 164.50M | 0.00M | 117.30M | 80.80M | 182.86M |
| Depreciation | 1.39M | 1.59M | 2.17M | 2.41M | 2.52M |
| Change to inventory | - | - | - | - | 1.25M |
| Change to account receivables | 2.10M | -1.56M | -0.31M | 2.50M | -0.50M |
| Sale purchase of stock | - | - | - | 3.52M | 3.67M |
| Other cashflows from financing activities | - | 2.75M | 0.78M | 3.52M | 3.67M |
| Change to netincome | - | - | - | 13.35M | 11.07M |
| Capital expenditures | 0.31M | 0.28M | 0.51M | 1.96M | 1.71M |
| Change receivables | - | - | - | 3.41M | -1.11M |
| Cash flows other operating | - | - | - | -2.10M | -0.54M |
| Cash and cash equivalents changes | - | - | - | -0.31M | -21.64M |
| Change in working capital | 3.91M | -4.25M | -4.61M | -3.09M | -11.89M |
| Stock based compensation | 12.47M | 14.55M | 14.80M | 13.35M | 11.07M |
| Other non cash items | -2.95M | -4.39M | -5.99M | 0.15M | 0.67M |
| Free cash flow | -60.38M | -2.50M | -91.47M | -99.01M | -80.19M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics Inc |
-0.03 0.67% |
3.69 | - | - | 2.66 | 0.93 | 117.40 | -3.09 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Bryan E. Stuart | Pres, CEO & Director | 1976 |
| Dr. Judith A. Dunn Ph.D. | Interim Chief Medical Officer | 1962 |
| Dr. Bradley E. Bernstein M.D., Ph.D. | Founder | NA |
| Dr. Michael R. Green | Founder | NA |
| Dr. Rudolf Jaenisch M.D., Ph.D. | Founder | NA |
| Prof. Jeannie T. Lee M.D., Ph.D. | Founder | NA |
| Dr. Danny Reinberg | Founder | NA |
| Ms. Esther P. Rajavelu | CFO & Treasurer | 1979 |
| Mr. Mel Hayes | Chief Operating Officer | 1970 |
| Mr. Gregory Tourangeau | Controller & Principal Accounting Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.